Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
ICON Clinical Research
Time Perspective : Most patients are expected to be a mix of retrospective and prospective data collection. Patients can be enrolled after their study index date (retrospective component) and have to be followed until 5 years from study index date are complete (time between enrollment and 5 year follow-up is the prospective component)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly-diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who started their first-line Tyrosine Kinase Inhibitor (TKI) treatment on imatinib, dasatinib or nilotinib in accordance with the timelines below
18 years or older at time of of CP-CML diagnosis
a) Imatinib Cohorts
Patients who started their first-line Imatinib treatment between January 2, 2008 and September 30, 2010.Patients fitting this criterion are defined as retrospective Imatinib patients
Patients who started their first-line Imatinib treatment on or after October 1, 2010
b) Dasatinib Cohort
Patients who started their first-line Dasatinib treatment after the drug was approved in this indication
c) Nilotinib Cohort
Patients who started their first-line Nilotinib treatment after the drug was approved in this indication
Patients are also eligible when they have already switched to a subsequent therapy (TKI or other) at the time of enrollment, as long as their first-line and subsequent CML treatment information is available at site for data entry into the study Electronic Case Report Form (eCRF)
Receiving treatment at medical practice (eg. community-based, office-based, hospital-based, academic setting, oncology center)
You may not be if
Patients who are participating in an interventional trial which may influence the management of their CML disease will be excluded
Discontinuation Criteria:
Enrolled patients who join an interventional trial which may influence the management of their CML disease will be excluded at the time of entry into the interventional trial
